A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Trial Profile

A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bexarotene; Methotrexate
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides
  • Focus Registrational; Therapeutic Use
  • Acronyms ALCANZA
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 09 Dec 2017 Results presented in a Seattle Genetics media release.
    • 09 Dec 2017 According to a Seattle Genetics media release, updated results were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 14 Nov 2017 According to a Takeda media release, based on the results of this trial, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval for the treatment of adult patients with CD30 positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top